.png){kind=icon}
.png){kind=icon}
Return
Real-world population pharmacokinetic modeling of elexacaftor, tezacaftor, and ivacaftor
.png){kind=icon}
PRE
AI
A
S
C
M
M
K
O
J
L
J
M
M
U
DOI：10.1016/j.jcf.2026.07.1984.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Target-attainment analysis identified patients with inadequate exposure requiring dose optimization. • Our Pharmacokinetic models describe substantial interindividual variability in CFTR modulator exposure. • Concomitant antifungal therapy significantly reduces clearance of elexacaftor, tezacaftor, and ivacaftor. • Higher albumin, bilirubin, and vitamins D and E are associated with modestly lower drug clearance.
Journal
IF:
6
Papers:
2.9K
Citations:
7.3K
Organization
Cited Papers